Please assess the completion status of the following clinical trial:

Trial Title: Pantoprazole on Insulin Secretion in Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus~* Drug-Naive~* No complications~* HbA1c 7 to \< 9%~* Fasting plasma glucose \< 210mg/dl~* Body mass index 30.0 to 39.9 and body weight stable for at least 3 months before the study~* Non smokers~* Blood pressure \< 130/80~Exclusion Criteria:~* Diabetes complications~* Women pregnant or stage of lactation~* Hepatic, renal, autoimmune disease~* Take drugs with effects on insulin secretion~* Zollinger-Ellison disease~* Gastric or pancreatic tumor.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo of calcined magnesia, capsules
- Pantoprazole (Type: EXPERIMENTAL): The pantoprazole will be administered in 40mg capsules

Based on this trial design, predict the completion outcome and termination type (if applicable).